Try a new search

Format these results:

Searched for:



Total Results:


Approach to Primary Care of the Male Patient

Chapter by: Lamm, Steven; Brill, Kenneth
in: Design and implementation of the modern men's health center : a multidisciplinary approach by Alukal, Joseph P; et al [Eds]
Cham, Switzerland : Springer, [2021]
pp. 13-34
ISBN: 9783030544812
CID: 5522442

Design and implementation of the modern men's health center : a multidisciplinary approach

Alukal, Joseph P; Lamm, Steven; Walsh, Thomas J
Cham, Switzerland : Springer, [2021]
Extent: xvi, 280 p. ; 25 cm
ISBN: 9783030544812
CID: 5522482

The obesity epidemic and sexual health

Chapter by: Lamm, Steven; Bekisz, Jonathan
in: Integrative sexual health by Bartlik, Barbara; Espinosa, Geo; Mindes, Janet (Eds)
New York, NY : Oxford University Press, [2018]
pp. ?-?
ISBN: 0190225882
CID: 3122392

An Interesting Case of Celiac Disease with Overlap with Other Autoimmune Conditions [Meeting Abstract]

Maurer, Katie; Lamm, Steven; Poppers, David
ISSN: 1572-0241
CID: 2492832

A Case of a Co-infection with Blastocystis and Spirochetosis in an Immunocompetent Homosexual Male [Meeting Abstract]

Adelsheimer, Andrew; Betesh, Andrea; Lamm, Steven; Poppers, David
ISSN: 1572-0241
CID: 2492772

Cardiovascular Effects of the New Weight Loss Agents

Vorsanger, Matthew H; Subramanyam, Pritha; Weintraub, Howard S; Lamm, Steven H; Underberg, James A; Gianos, Eugenia; Goldberg, Ira J; Schwartzbard, Arthur Z
The global obesity epidemic and its impact on cardiovascular outcomes is a topic of ongoing debate and investigation in the cardiology community. It is well known that obesity is associated with multiple cardiovascular risk factors. Although life-style changes are the first line of therapy, they are often insufficient in achieving weight loss goals. Liraglutide, naltrexone/bupropion, and phentermine/topiramate are new agents that have been recently approved to treat obesity, but their effects on cardiovascular risk factors and outcomes are not well described. This review summarizes data currently available for these novel agents regarding drug safety, effects on major cardiovascular risk factors, impact on cardiovascular outcomes, outcomes research that is currently in progress, and areas of uncertainty. Given the impact of obesity on cardiovascular health, there is a pressing clinical need to understand the effects of these agents beyond weight loss alone.
PMID: 27539178
ISSN: 1558-3597
CID: 2219452

Obesity and Hypogonadism

Lamm, Steven; Chidakel, Aaron; Bansal, Rohan
The relationship between obesity and hypogonadism is complicated. The relationship is bidirectional and there are numerous causative and correlative factors on both sides of the equation. Obesity is increasing in prevalence in epidemic proportions. Likewise, we are beginning to see the rapid increase in the incidence of male hypogonadism. It is only recently that we are learning the ways in which these 2 conditions exacerbate each other, and we are only beginning to understand how by treating one of these conditions, we can help to treat the other as well.
PMID: 27132582
ISSN: 1558-318x
CID: 2100702

Your Guide to Making Prostate Cancer Treatment Decisions [General Interest Article]

Lamm, Steven; Lepor, Herbert; Sperling, Dan
ISSN: 1544-5488
CID: 824942

Experts explain [General Interest Article]

Lamm, Steven
ISSN: 1536-5980
CID: 824962

Life after Prostate Cancer Treatment [General Interest Article]

Lamm, Steven; Lepor, Herbert; Sperling, Dan
ISSN: 1544-5488
CID: 824952